Research Biokin bispecific ADC iza-bren hits goal in lung cancer trial, boosting case for BMS’ global testBy Healthcare Propulsion StaffAugust 18, 20260 Biokin Pharma’s iza-bren, a first-in-class antibody-drug conjugate partnered with Bristol Myers Squibb, has posted another positive phase 3 readout. The…
Research It’s BMS vs. Celgene investors once more after US appeals court revives lawsuitBy Healthcare Propulsion StaffAugust 14, 20260 A federal appeals court has overturned (PDF) the 2024 dismissal of a lawsuit filed by Celgene shareholders that accuses Bristol…
Research BMS bags first FDA approval for CELMoD franchise with Zenbexus multiple myeloma nodBy Healthcare Propulsion StaffAugust 14, 20260 In a historic breakthrough for targeted protein degradation, Bristol Myers Squibb has secured the first FDA approval for a CELMoD…
